Dezima Pharma BV, which is developing drugs for dyslipidemia, has appointed Rob de Ree as its new chief executive officer. Mr de Ree has more than 20 years of experience in sales and marketing, business development and general management in the pharmaceutical and medical devices industries including holding positions at Medtronic Inc and Crucell, which is now part of Johnson & Johnson Inc. Most recently, he was chief executive of the cardiovascular monitoring company, BMEYE BV which was sold to Edwards Lifesciences in 2012.
Dezima announced the appointment on 12 June 2013.
Copyright 2013 Evernow Publishing Ltd